AIM: To determine whether -1195 A-->G and/or -765 G-->C polymorphisms in Cyclooxygenase-2 (COX-2) may have a risk modifying effect on the development of esophageal carcinoma in a Dutch Caucasian population. METHODS: Two study groups were recruited, 252 patients with esophageal carcinoma and 240 healthy controls, matched for race, age, gender and recruiting area. DNA was isolated from whole blood and used for genotyping. PCR products were digested with restriction enzymes and products were analyzed by agarose gel electrophoresis. Odds ratios (OR) and 95% confidence intervals (CI) were estimated. RESULTS: The distribution of the -1195 A-->G polymorphism was significantly different in esophageal cancer patients compared to controls. The -1195 GG genotype resulted in a higher risk of developing esophageal adenocarcinoma (OR = 3.85, 95% CI: 1.45-10.3) compared with the -1195 AA genotype as a reference. The -765 G-->C genotype distribution was not different between the two groups. The GG/GG haplotype was present more often in esophageal adenocarcinoma patients than in controls (OR = 3.45, 95% CI: 1.24-9.58; with AG/AG as a reference). The same trends were observed in patients with squamous cell carcinomas, however, the results did not reach statistical significance. CONCLUSION: Presence of the COX-2 -1195 GG genotype and of the GG/GG haplotype may result in a higher risk of developing esophageal carcinoma.
AIM: To determine whether -1195 A-->G and/or -765 G-->C polymorphisms in Cyclooxygenase-2 (COX-2) may have a risk modifying effect on the development of esophageal carcinoma in a Dutch Caucasian population. METHODS: Two study groups were recruited, 252 patients with esophageal carcinoma and 240 healthy controls, matched for race, age, gender and recruiting area. DNA was isolated from whole blood and used for genotyping. PCR products were digested with restriction enzymes and products were analyzed by agarose gel electrophoresis. Odds ratios (OR) and 95% confidence intervals (CI) were estimated. RESULTS: The distribution of the -1195 A-->G polymorphism was significantly different in esophageal cancerpatients compared to controls. The -1195 GG genotype resulted in a higher risk of developing esophageal adenocarcinoma (OR = 3.85, 95% CI: 1.45-10.3) compared with the -1195 AA genotype as a reference. The -765 G-->C genotype distribution was not different between the two groups. The GG/GG haplotype was present more often in esophageal adenocarcinomapatients than in controls (OR = 3.45, 95% CI: 1.24-9.58; with AG/AG as a reference). The same trends were observed in patients with squamous cell carcinomas, however, the results did not reach statistical significance. CONCLUSION: Presence of the COX-2 -1195 GG genotype and of the GG/GG haplotype may result in a higher risk of developing esophageal carcinoma.
Authors: Anastasia Papafili; Michael R Hill; David J Brull; Robin J McAnulty; Richard P Marshall; Steve E Humphries; Geoffrey J Laurent Journal: Arterioscler Thromb Vasc Biol Date: 2002-10-01 Impact factor: 8.311
Authors: N V Chandrasekharan; Hu Dai; K Lamar Turepu Roos; Nathan K Evanson; Joshua Tomsik; Terry S Elton; Daniel L Simmons Journal: Proc Natl Acad Sci U S A Date: 2002-09-19 Impact factor: 11.205
Authors: Christianne J Buskens; Bastiaan P Van Rees; Anna Sivula; Johannes B Reitsma; Caj Haglund; Piter J Bosma; G Johan A Offerhaus; J Jan B Van Lanschot; Ari Ristimäki Journal: Gastroenterology Date: 2002-06 Impact factor: 22.682
Authors: Mark M T J Broekman; Caro Bos; René H M Te Morsche; Frank Hoentjen; Hennie M J Roelofs; Wilbert H M Peters; Geert J A Wanten; Dirk J de Jong Journal: J Hum Genet Date: 2014-09-04 Impact factor: 3.172
Authors: James Y Dai; Jean de Dieu Tapsoba; Matthew F Buas; Lynn E Onstad; David M Levine; Harvey A Risch; Wong-Ho Chow; Leslie Bernstein; Weimin Ye; Jesper Lagergren; Nigel C Bird; Douglas A Corley; Nicholas J Shaheen; Anna H Wu; Brian J Reid; Laura J Hardie; David C Whiteman; Thomas L Vaughan Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-09-16 Impact factor: 4.254
Authors: Thorunn Rafnar; Gudbjorg R Sigurjonsdottir; Simon N Stacey; Gisli Halldorsson; Patrick Sulem; Luba M Pardo; Hannes Helgason; Stefan T Sigurdsson; Thorkell Gudjonsson; Laufey Tryggvadottir; Gudridur H Olafsdottir; Jon G Jonasson; Kristin Alexiusdottir; Asgeir Sigurdsson; Julius Gudmundsson; Jona Saemundsdottir; Jon K Sigurdsson; Hrefna Johannsdottir; Andre Uitterlinden; Sita H Vermeulen; Tessel E Galesloot; Dawn C Allain; Martin Lacko; Bardur Sigurgeirsson; Kristin Thorisdottir; Oskar T Johannsson; Fridbjorn Sigurdsson; Gunnar B Ragnarsson; Helgi Isaksson; Hronn Hardardottir; Tomas Gudbjartsson; Daniel F Gudbjartsson; Gisli Masson; Lambertus A M L Kiemeney; Amanda Ewart Toland; Tamar Nijsten; Wilbert H M Peters; Jon H Olafsson; Steinn Jonsson; Unnur Thorsteinsdottir; Gudmar Thorleifsson; Kari Stefansson Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506
Authors: Matthew F Buas; Qianchuan He; Lisa G Johnson; Lynn Onstad; David M Levine; Aaron P Thrift; Puya Gharahkhani; Claire Palles; Jesper Lagergren; Rebecca C Fitzgerald; Weimin Ye; Carlos Caldas; Nigel C Bird; Nicholas J Shaheen; Leslie Bernstein; Marilie D Gammon; Anna H Wu; Laura J Hardie; Paul D Pharoah; Geoffrey Liu; Prassad Iyer; Douglas A Corley; Harvey A Risch; Wong-Ho Chow; Hans Prenen; Laura Chegwidden; Sharon Love; Stephen Attwood; Paul Moayyedi; David MacDonald; Rebecca Harrison; Peter Watson; Hugh Barr; John deCaestecker; Ian Tomlinson; Janusz Jankowski; David C Whiteman; Stuart MacGregor; Thomas L Vaughan; Margaret M Madeleine Journal: Gut Date: 2016-08-02 Impact factor: 23.059